Saturday, October 3, 2026

USD/EUR Over 2% Down In The Last 21 Sessions

USD/EUR Over 2% Down In The Last 21 Sessions

(VIANEWS) - USD/EUR (USDEUR) has been up by 2% for the last 21 sessions. At 07:13 EST on Saturday, 25 March, USD/EUR (USDEUR) is $0.93.

USD/EUR's yearly highs and lows, it's 3.903% up from its 52-week low and 11.362% down from its 52-week high.

Volatility

USD/EUR's last week, last month's, and last quarter's current intraday variation average was a negative 0.60%, a negative 0.12%, and a positive 0.47%, respectively.

USD/EUR's highest amplitude of average volatility was 0.60% (last week), 0.56% (last month), and 0.47% (last quarter), respectively.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, USD/EUR's Forex is considered to be overbought (>=80).

News about

  • Eur/usd price analysis: refreshes seven-week top near 1.0930, pokes the last defense of bears. According to FXStreet on Thursday, 23 March, "On the flip side, a one-week-old ascending support line, close to 1.0800, puts a floor under the EUR/USD price.", "It should be noted that a downward-sloping resistance line from May 2022, around 1.0950 by the press time, also acts as a short-term upside filter for the EUR/USD pair."
  • Eur/usd is now officially eyeing the 1.1000 level – ING. According to FXStreet on Thursday, 23 March, "The next key handle for EUR/USD is 1.1000: that is an important benchmark level that may see some significant resistance unless markets feel substantially confident the worst of the banking shock - especially in Europe - is past us.", "All this points to a supported EUR/USD in the remainder of this year and we target 1.15 in the second half of 2023."
  • Eur/usd price analysis: bulls eyes multi-month-old resistance as euro approaches 1.0900. According to FXStreet on Thursday, 23 March, "Additionally, bullish MACD signals and the firmer Relative Strength Index (RSI) line, not overbought, also underpin the bullish bias about the EUR/USD pair.", "It should be noted that the 200-DMA level surrounding 1.0335 acts as the last defense of the EUR/USD buyers."
  • Eur/usd forecast: euro faces uncertainty and resistance - 23 March 2023. According to DailyForex on Thursday, 23 March, "The EUR/USD currency pair experienced a slight rally during Wednesday's trading session, testing the 1.08 level, an area known for its previous resistance. ", "It is essential for investors to stay informed and adapt to the evolving market conditions, especially given the upcoming FOMC meeting and its potential impact on the EUR/USD currency pair."
  • Eur/usd seen moving lower to 1.02 in six-month horizon – danske bank. According to FXStreet on Thursday, 23 March, "Relative rates have favoured EUR after the more hawkish ECB last week, but a prolonged rally in EUR/USD could support a renewed uptick in commodity prices and inflation expectations, and thus hinder a return to 2% inflation."

More news about USD/EUR (USDEUR).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com